GLP1R and diabetic kidney disease: Another future potential of AI in the management of DKD, particularly in light of the observed renal benefits of newer drugs like SGLT 2 inhibitors and GLP-1 receptor agonists [25], lies in leveraging multiple omics platforms and deep learning models to uncover patient-level disease characteristics and individualized treatment responses.